2023 World Conference on Lung Cancer (Posters)-P1.17. Lung-Cancer Screening: Is It Worth Investing? Evidence from a Population-Based Markov Study in Italy

P1.17. Lung-Cancer Screening: Is It Worth Investing? Evidence from a Population-Based Markov Study in Italy - PDF(Abstract)

Back to course

Pdf Summary

This study examines the cost-effectiveness of a population-based lung cancer screening program in Italy. The objective is to assess whether the program, targeting high-risk individuals aged 55 to 74 years who are prior or current heavy smokers, is worth investing in. The study uses a dynamic cohort-based Markov model to simulate the natural history of disease progression and the treatment and aftercare paths corresponding to different stages of lung cancer. The outcomes measured are incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB), with costs and quality-adjusted life years (QALYs) as the key variables. <br /><br />The results of the simulation, based on a high-risk population of 444,029 individuals in Italy, show that the screening program leads to an incremental gain of 52,141 to 81,236 QALYs over 15 years, with an incremental budget impact of 771 million to 1.3 billion euros across four screening scenarios. The ICERs for the LDCT-based annual screening program range from 14,527 to 16,040 per QALY gained compared to standard clinical care. <br /><br />The study concludes that population-based LDCT lung cancer screening is cost-effective for several different screening invitation scenarios. The findings provide robust support for policy makers, payers, and guideline developers who are considering implementing life-saving lung cancer screening programs. <br /><br />Keywords: Lung cancer screening, cost-effectiveness, population study. <br /><br />This study falls under the "Screening and Early Detection" track at the WCLC 2023 conference. It is a regular abstract presentation.

Asset Subtitle

Pierluigi Novellis

Meta Tag

Speaker Pierluigi Novellis

Topic Screening & Early Detection: Program Design

Keywords

lung cancer screening

cost-effectiveness

population-based

Italy

high-risk individuals

smokers

Markov model

incremental cost-effectiveness ratio

net monetary benefit

QALYs